Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19

Infectious disease immunotherapies – An update: Revisiting an age-old adage in times of COVID-19

Show other versions (1)

This review article tries to bring together the important active and passive immunotherapeutic modalities currently under consideration for COVID-19 disease. The basis of immunotherapy is based on use of naturally occurring agents or drugs to modify the body's immune response to certain antigen...

Full description

Bibliographic Details
Main Authors:	Mahima Lall, Suyash Singh, Amar Atal, Anuj Singhal
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Journal of Marine Medical Society
Subjects:	clinical trials convalescent plasma therapy covid-19 immunotherapy
Online Access:	http://www.marinemedicalsociety.in/article.asp?issn=0975-3605;year=2021;volume=23;issue=1;spage=10;epage=15;aulast=Lall

Similar Items

Infectious disease immunotherapies: An update, revisiting an age-old adage in times of COVID-19
by: A T Atal, et al.
Published: (2021-01-01)

Convalescent Plasma: An Old Trick for the Treatment of COVID-19
by: Reza Jafari, et al.
Published: (2020-07-01)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
by: Focosi Daniele, et al.
Published: (2021-01-01)

Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective
by: Saly Kanj, et al.
Published: (2021-05-01)

Challenges in the collection of convalescent plasma for COVID-19 patients at a plasma therapy trial site
by: Nidhi Bhatnagar, et al.
Published: (2020-01-01)

Reinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial
by: Joan Bargay-Lleonart, et al.
Published: (2022-05-01)

Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study
by: Manuel Rojas, et al.
Published: (2022-06-01)

Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control
by: P. Cacilhas, et al.
Published: (2022-09-01)

Issues with reporting and interpretation of Khan et al. 2021
by: Nicholas J. DeVito, et al.
Published: (2022-06-01)

Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic
by: Maria Puopolo, et al.
Published: (2022-06-01)

Why will it never be known if convalescent plasma is effective for COVID-19
by: Manuel Rojas, et al.
Published: (2020-01-01)

Compassionate Use of GC5131 (Hyperimmunoglobulin) Therapy in Critically Ill Patients Diagnosed with COVID-19: A Case Series and Review of Literature
by: Sunha Choi, et al.
Published: (2021-09-01)

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy
by: Hayder Al-Momen, et al.
Published: (2020-07-01)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
by: Daniele Focosi, et al.
Published: (2023-08-01)

"Adage".
by: Chiok, Teresa Enqi.
Published: (2013)

Hyperimmune Globulins for the Management of Infectious Diseases
by: Ilaria Pati, et al.
Published: (2023-07-01)

Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions
by: Jayanth Seshan, et al.
Published: (2020-09-01)

Is convalescent plasma therapy effective for COVID-19? Our initial experience at tertiary care center
by: Neha Jayant Hurkat, et al.
Published: (2021-01-01)

Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
by: Paola Maria Manzini, et al.
Published: (2022-11-01)

Immunotherapy for Recurrent Glioma—From Bench to Bedside
by: Yi Pu, et al.
Published: (2023-06-01)

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
by: Yaseen M. Arabi, et al.
Published: (2016-09-01)

Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia
by: Heba K. Nabih
Published: (2021-02-01)

Convalescent Plasma Therapy and its Century-Old Untapped Potential for COVID-19
by: Samahir Tariq Khan, et al.
Published: (2020-12-01)

Cancer Nano-Immunotherapy: The Novel and Promising Weapon to Fight Cancer
by: Daniel J. García-Domínguez, et al.
Published: (2024-01-01)

Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19
by: Sixten Körper, et al.
Published: (2022-10-01)

Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
by: Elena Diago-Sempere, et al.
Published: (2021-01-01)

Standard of care in immunotherapy trials: Challenges and considerations
by: Gareth Rivalland, et al.
Published: (2017-09-01)

Informative Censoring—A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data
by: Hung-Mo Lin, et al.
Published: (2023-01-01)

Rapid Clinical and Radiological Improvement in a Patient with Severe COVID-19 Infection Treated with Convalescent Plasma
by: Stephen Malnick, et al.
Published: (2021-05-01)

Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
by: Anna Moniuszko-Malinowska, et al.
Published: (2020-12-01)

Potential predictors of outcomes among hospitalized COVID-19 patients treated with convalescent plasma: a single-center study
by: Sridhar Chilimuri, et al.
Published: (2021-07-01)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
by: Arturo Casadevall, et al.
Published: (2021-06-01)

Immunotherapy trials in Parkinson’s disease: challenges
by: Bin Xiao, et al.
Published: (2023-03-01)

Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
by: Wesley H. Self, et al.
Published: (2021-03-01)

“Publish or Perish”; time to question an age old adage?
by: Darshana Sanghvi
Published: (2021-01-01)

Convalescent plasma: A potential therapeutic option for COVID-19 patients
by: Swee Li Ng, et al.
Published: (2020-01-01)

Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma
by: Armando M. Perichon, et al.
Published: (2023-12-01)

Conventional cancer immunotherapies: assessing progress and envisioning future possibilities
by: Paul Yiran Ntasin, et al.
Published: (2023-09-01)

The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review
by: Massimo Franchini, et al.
Published: (2023-12-01)

Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial
by: Alonso Soto, et al.
Published: (2021-05-01)